Transfer-factor (IMUNOR) administration in women with chronic vulvovaginal discomfort: clinical study results

Česká verzia

Authors: Vít Unzeitig ^1,2; Jan Kestřánek ³; Jiří Špaček ³
Authors place of work: Centrum ambulantní gynekologie a primární péče Brno ¹; Gynekologicko-porodnická klinika MU a FN Brno ²; Gynekologicko-porodnická klinika UK a FN Hradec Králové ³
Published in the journal: Prakt Gyn 2012; 16(1): 3-6
Category: Gynecology and Obstetrics

Summary

A study on the effect of administration of the transfer-factor (IMUNOR) on the changes in subjective complaints in women suffering from chronic vulvovaginal discomfort of unclear etiology. The patients themselves assessed their subjective complaints based on their intensity using a 0–10 scale rating system. 28 women at fertile age were included in the study. After the loading dose was administered, IMUNOR 10mg was taken on an empty stomach once a week for a period of 3 months.

Results:
46 % of the patients reported a significant improvement or even passing of their complaints (the score at the end of the study was lower by over 71 %), 33 % reported improvement (the final score decreased by 31–70 %) and only 21 % of the participants stated just a small or no improvement at all of their condition.

Conclusion:
the administration of the IMUNOR 10mg transfer-factor led to the improvement in the chronic vulvovaginal discomfort in almost 80 % of the study participants.

Key words:
IMUNOR – transfer-factor – vulvovaginal discomfort

Zdroje

1. Mardh PA, Rodrigues AG, Genc M et al. Facts and myths on recurrent vulvovaginal candidosis – a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy. [Review]. International Journal of STD & AIDS 2002; 13(8): 522–539.

2. Ledger WJ, Witkin SS. Vulvovaginal infections. London: Manson Publish 2007.

3. Witkin SS, Linhares IM, Giraldo P. Bacterial flora of the female genital tract: function and immune regulation. Best Pract Res Clin Obstet Gynaecol 2007, 21(3): 347–354.

4. Patel D, Gillespie B, Sobel J et al. Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: results of a prospective cohort study. Am J Obst Gynaecol 2004; 190(3): 644–653.

5. Falagas ME, Betsi GI, Athanasiou S. Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. The Journal of Antimicrobial Chemotherapy 2006; 58(2): 166–174.